• DOI:10.1007/s12272-013-0106-6
• Corpus ID: 2554248

The ameliorating effects of 5,7-dihydroxy-6-methoxy-2(4-phenoxyphenyl)-4H-chromene-4-one, an oroxylin A derivative, against memory impairment and sensorimotor gating deficit in mice

@article{Liu2013TheAE,
  title={The ameliorating effects of 5,7-dihydroxy-6-methoxy-2(4-phenoxyphenyl)-4H-chromene-4-one, an oroxylin A derivative, against memory impairment and sensorimotor gating deficit in mice},
  author={Xiaotong Liu and Sung In Hong and Se Jin Park and June Bryan I. de la Pe{\~n}a and Haiyan Che and Seo Young Yoon and Dong-Hyun Kim and Jong Min Kim and Mudan Cai and Victoria B. Risbrough and Mark A Geyer and Chan Young Shin and Jae Hoon Cheong and Haeil Park and Jae-hwan Lew and Jong Hoon Ryu},
  journal={Archives of Pharmacal Research},
  year={2013},
  volume={36},
  pages={854-863}
}

• Xiaotong Liu, S. Hong, +13 authors J. Ryu
• Published 31 March 2013
• Biology, Psychology
• Archives of Pharmacal Research

We previously reported that oroxylin A, a γ-aminobutyric acid A (GABAA) receptor antagonist, ameliorates drugs-induced memory impairments. We synthesized several oroxylin A derivatives in efforts to find a substance that has pro-cognitive effects as well as improves sensorimotor gating. The aim of the present study is to investigate the effect of a novel oroxylin A derivative, 5,7-dihydroxy-6-methoxy-2(4-phenoxyphenyl)-4H-chromene-4-one (DMPC), on pharmacological models of schizophrenia, which exhibit memory impairment and sensorimotor gating deficit. Memory impairment was induced by scopolamine, a muscarinic receptor antagonist, or MK-801, an N-methyl-d-aspartate receptor antagonist. Sensorimotor gating deficits were induced by MK-801 and measured by prepulse inhibition (PPI) of the acoustic startle response task. DMPC treatment (20 mg/kg) significantly attenuated scopolamine- or MK-801-induced memory impairment and it even enhanced cognitive performance of normal animals. Furthermore, DMPC significantly ameliorated MK-801-induced PPI deficits in the acoustic startle response task. In an in vitro study, DMPC (20 μM) inhibited intracellular Cl− influx induced by muscimol, a selective GABAA receptor agonist. These results suggest that DMPC would be a potential candidate for alleviating cognitive dysfunction and sensorimotor gating deficits in schizophrenia, and that its effects may be mediated, in part, via blockade of the GABAergic neurotransmitter system.